We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Lateral Flow Immunoassay Evaluated for Respiratory Samples

By LabMedica International staff writers
Posted on 08 Jan 2013
Rapid point-of-care pathogen detection remains a challenge, especially for Staphylococcus aureus detection in respiratory samples.

A rapid S. aureus–specific lateral flow immunochromatography (LFI) test has been developed using a specific monoclonal antibody to the S. aureus cell-wall peptidoglycan.

Scientists at King's College London (UK) used a LFI strip and modified the antigen target and capture/detection antibody to achieve greater sensitivity and specificity. They used an affinity-purified mouse monoclonal anti-S. aureus antibody that was raised specifically against S. aureus cell-wall peptidoglycan and conjugated with gold colloid. They used samples from six volunteers with severe asthma as well as spiked sputum and bronchial lavage specimens.

The LFI test was shown to be specific for S. aureus with no signal development for other Staphylococcal species or common respiratory pathogens. Evaluation of S. aureus isolates spiked into induced sputum and bronchoalveolar lavage samples derived from severe asthmatic patients showed a detection limit of 106 colony forming units (CFU)/mL for the LFI. The LFI test strips positively detected methicillin-sensitive S. aureus (MSSA), methicillin-resistant S. aureus (MRSA). The test was also shown to successfully detect S. aureus in one sample independently determined to be S. aureus positive by quantitative polymerase chain reaction.

The authors concluded that that an LFI detection limit of equal to or greater than 106 CFU/mL may be sufficiently sensitive to screen for preliminary information in a number of applications, but LFI tests with lower detection limits of less than 104 CFU/mL would be more clinically relevant. Further studies are currently ongoing to lower the detection limits of the LFI test and evaluate the robustness of the assay for a number of different applications. The ability of the LFI test to rapidly detect S. aureus in clinical respiratory samples suggests that it might be a useful platform for further development of point-of-care diagnostic applications. The study was published in the January 2013 edition of the journal Diagnostic Microbiology & Infectious Diseases.

Related Links:
King's College London



Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Bordetella Pertussis Molecular Assay
Alethia Pertussis
New
Biological Indicator Vials
BI-O.K.
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The experimental blood test accurately indicates severity and predicts potential recovery from spinal cord injury (Photo courtesy of 123RF)

Blood Test Identifies Multiple Biomarkers for Rapid Diagnosis of Spinal Cord Injury

The National Institutes of Health estimates that 18,000 individuals in the United States sustain spinal cord injuries (SCIs) annually, resulting in a staggering financial burden of over USD 9.... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Industry

view channel
Image: Tumor-associated macrophages visualized using the Multiomic LS Assay (Photo courtesy of ACD)

Leica Biosystems and Bio-Techne Expand Spatial Multiomic Collaboration

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD, Newark, CA, USA), and Leica Biosystems (Nussloch,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.